AbbVie 8-K Details Financial Condition, Senior Notes on Feb 2

Ticker: ABBV · Form: 8-K · Filed: 2024-02-02T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, debt, corporate-filing

TL;DR

**AbbVie just dropped an 8-K with fresh financial results and debt info, so check it out.**

AI Summary

AbbVie Inc. filed an 8-K on February 2, 2024, reporting on its results of operations and financial condition. This filing indicates that AbbVie is providing updated financial information, including details on various senior notes such as the 1.375% Senior Notes due 2024 and 2.125% Senior Notes due 2029. This matters to investors because it provides current financial health and operational performance data, which can influence stock valuation and future dividend decisions.

Why It Matters

This filing provides investors with the latest financial and operational data for AbbVie, crucial for assessing the company's health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not indicate any immediate new risks.

Analyst Insight

A smart investor would review the full financial statements and exhibits referenced in this 8-K to understand the specifics of AbbVie's operational results and debt structure, especially concerning the senior notes maturing in 2024, to assess the company's liquidity and financial stability.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of AbbVie Inc.'s 8-K filing dated February 2, 2024?

The 8-K filing by AbbVie Inc. on February 2, 2024, is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.

What specific financial instruments are mentioned in the filing with their respective interest rates and maturity dates?

The filing mentions several senior notes, including 1.375% Senior Notes due 2024, 1.250% Senior Notes due 2024, 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031.

What is AbbVie Inc.'s business address and phone number as stated in the filing?

AbbVie Inc.'s business address is 1 North Waukegan Road, North Chicago, Illinois 60064-6400, and its telephone number is (847) 932-7900.

What is the Central Index Key (CIK) for AbbVie Inc.?

The Central Index Key (CIK) for AbbVie Inc. is 0001551152.

Under which SEC Act was this 8-K form filed?

This 8-K form was filed under the 1934 Act.

From the Filing

0001551152-24-000007.txt : 20240202 0001551152-24-000007.hdr.sgml : 20240202 20240202075116 ACCESSION NUMBER: 0001551152-24-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240202 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24588828 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240202.htm 8-K abbv-20240202 0001551152 false 0001551152 2024-02-02 2024-02-02 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-02-02 2024-02-02 0001551152 exch:XNYS us-gaap:CommonStockMember 2024-02-02 2024-02-02 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec1250SeniorNotesDue2024Member 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-02-02 2024-02-02 0001551152 exch:XNYS abbv:Sec1250SeniorNotesDue2031Member 2024-02-02 2024-02-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 2, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other jurisdiction   (Commission File Number)   (IRS Employer of incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐                        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Sto

View on Read The Filing